Beijing Mabworks Biotech Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 8 to 13, 2027 · next Feb 8
- 1 fee due Mar 24, 2027The maintenance fee for Antibodies binding human Claudin 18.2 and uses thereof (US 10,421,817) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Antibodies binding OX40 and uses thereof (US 10,442,866) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Antibodies Binding CD40 and Uses Thereof (US 10,570,210) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 1 fee due Sep 3, 2027The maintenance fee for Antibodies binding VISTA and uses thereof (US 10,577,424) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Anti-CD20 antibody (US 11,970,541) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 20 US 12,767,725 Single-Chain Fragment Variable Comprising Mutant Light Chain Framework Region
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,377,833 | Bispecific anti-HER2 antibody In force · USPTO record | In force | USPTO record | |
| US 11,208,492 | Anti-CD20 antibody In force · USPTO record | In force | USPTO record | |
| US 11,970,541 | Anti-CD20 antibody In force · USPTO record | In force | USPTO record | |
| US 10,421,817 | Antibodies binding human Claudin 18.2 and uses thereof In force · USPTO record | In force | USPTO record | |
| US 10,442,866 | Antibodies binding OX40 and uses thereof In force · USPTO record | In force | USPTO record | |
| US 10,570,210 | Antibodies Binding CD40 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,577,424 | Antibodies binding VISTA and uses thereof In force · USPTO record | In force | USPTO record | |
| US 10,946,092 | Antibodies binding LAG3 and methods of treatment using them In force · USPTO record | In force | USPTO record | |
| US 12,180,280 | Antibodies Binding Human and Monkey CD3 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,718,674 | Antibodies binding PD-L1 and uses thereof In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 13: 7 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 no status recorded